Helicobacter and gastric cancer disease mechanisms: Host response and disease susceptibility

Current Gastroenterology Reports

Volumn 5, Issue 6, 2003, Pages 459-467

  Li, Hanchen ^a   Stoicov, Calin ^a   Cai, Xun ^a   Wang, Timothy C ^a   Houghton, JeanMarie ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; APC PROTEIN; CYCLOOXYGENASE 2; FRAGILE HISTIDINE TRIAD PROTEIN; GAMMA INTERFERON; GASTRIN 17; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 8; PROGASTRIN; TUMOR NECROSIS FACTOR ALPHA; UVOMORULIN; VASCULOTROPIN; CADHERIN; GASTRIN;

APOPTOSIS; CANCER CLASSIFICATION; CANCER RISK; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; ENVIRONMENTAL FACTOR; GENE MUTATION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HIGH RISK POPULATION; HOST SUSCEPTIBILITY; HUMAN; IMMUNE RESPONSE; INFECTION CONTROL; NONHUMAN; NUTRITION; PROMOTER REGION; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH ACID SECRETION; STOMACH CANCER; TREATMENT OUTCOME; ANIMAL; GENETICS; IMMUNOLOGY; MICROBIOLOGY; PHYSIOLOGY; PRECANCER; STOMACH TUMOR;

ANIMALS; CADHERINS; DISEASE SUSCEPTIBILITY; GASTRINS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECANCEROUS CONDITIONS; STOMACH NEOPLASMS;

EID: 1542435362     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-003-0034-6     Document Type: Review

References (53)

1. Parkin DM, Laara E, Muir CS: Estimates of the worldwide frequency of sixteen major cancers in 1980. Int J Cancer 1988, 41:184-197.
2. Landis SH, Murray T, Bolden et al.: Cancer statistics, 1999. CA Cancer J Clin 1999, 49:8-31.
3. Neugut AI, Hayek M, Howe G: Epidemiology of gastric cancer. Semin Oncol 1996, 23:281-291.
4. Chan AO, Wong BC, Lam SK: Gastric cancer: past, present and future. Can J Gastroenterol 2001, 15:469-474.
5. Kuipers EJ, Uyterlinde AM, Pena AS, et al.: Long-term sequelae of Helicobacter pylori gastritis. Lancet 1995, 345:1525-1528.
6. Fuchs CS, Mayer RJ: Gastric carcinoma. N Engl J Med 1995, 333:32-41.
7. Correa P: Human gastric carcinogenesis: a multistep and multifactorial process. First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992, 52:6735-6740.
8. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans: Schistosomes, liver flukes and Helicobacter pylori. Lyon, France. June 7-14, 1994. Monogr Eval Carcinog Risks Hum 1994, 61:1-241.
9. Ekstrom AM, Held M, Hanson LE, et al.: Helicobacter pylori in gastric cancer established by CagA immunoblot as a marker of past infection. Gastroenterology 2001, 21:784-791.
10. Uemura N, Okamoto S, Yamamoto S, et al.: Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001, 345:784-789.
11. Segal ED, Cha J, Lo J, et al.: Altered states: involvement of phosphorylated CagA in the induction of host cellular growth changes by Helicobacter pylori. Proc Natl Acad Sci U S A 1999, 96:14559-14564.
12. Tummurau MK, Sharma SA, Blaser MJ: Helicobacter pylori picB, a homologue of the Bordetella pertussis toxin secretion protein, is required for induction of IL-8 in gastric epithelial cells. Mol Microbiol 1995, 8:867-876.
13. Wang TC, Goldenring JR, Dangler C, et al.: Mice lacking secretory phospholipase A2 show altered apoptosis and differentiation with Helicobacter felis infection Gastroenterology 1998, 14:675-689.
14. Sutton P, Kolesnikov T, Danon S, et al.: Dominant nonresponsiveness to Helicobacter pylori infection is associated with production of interleukin 10 but not gamma interferon. Infect Immun 2000, 68:4802-4804.
15. Eaton KA, Mefford M, Thevenot T: The role of T cell subsets and cytokines in the pathogenesis of Helicobacter pylori gastritis in mice. J Immunol 2001, 66:7456-7461.
16. Roth KA, Kapadia SB, Martin SM, et al.: Cellular immune responses are essential for the development of Helicobacterelis-associated gastric pathology. J Immunol 1999, 63:1490-1497.
17. Smythies LE, Waites KB, Lindsey JR, et al.: Helicobacter pylori-induced mucosal inflammation is Th1 mediated and exacerbated in IL-4 but not IFN-gamma, gene-deficient mice. J Immunol 2000, 165:1022-1029.
18. Fox JG, Beck P, Dangler CA, et al.: Concurrent enteric helminth infection modulates inflammation, gastric immune responses and reduces Helicobacter induced gastric atrophy. Nat Med 2000, 6:536-542.
19. Stoicov C, Li H, Lee FS, et al.: Concurrent Toxoplasma gondii infection allows a resistant host to mount an overwhelming Th1 response to Helicobacter infection [abstract]. Gastroenterology 2003, 124:A-12
20. Lehtola J: Family study of gastric carcinoma, with special reference to histological types. Scand J Gastroenterol 1978, 50 (Suppl):3-54.
21. El-Omar EM, Oien K, Murray LS, et al.: Increased prevalence of precancerous changes in relatives of gastric cancer patients: critical role of H. pylori. Gastroenterology 2000, 118:22-30.
22. Enders KW, Chan WY, Auyeung A, et al.: Increased frequency of pre-malignant gastric lesions in first degree relatives of stomach cancer patients [abstract]. Gastroenterology 2002, 122(Suppl 1):136.
23. El-Omar EM, Carrington M, Chow WH, et al.: Interleukin 1 polymorphisms associated with increased risk of gastric cancer. Nature 2000, 404:398-402.
24. El-Omar EM, Rabkin CS, Gammon MD et al.: Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology 2003, 124:1193-1201.
25. Houghton J, Macera-Bloch LS, Harrison L, et al.: Tumor necrosis factor alpha and interleukin 1beta up-regulate gastric mucosal Fas antigen expression in Helicobacter pylori infection. Infect Immun 2000, 68:1189-1195.
26. Houghton J, Macera-Bloch LS, Goldstein M, et al.: In vivo disruption of the Fas pathway abrogates gastric growth alterations secondary to Helicobacter infection. J Infect Diseases 2000, 182:856-864.
27. Li H, Stoicov C, Houghton, J: Fas Ag ligation signals for apoptosis or proliferation in gastric mucosal cells: the importance of receptor abundance [abstract]. Gastroenterology 2003, 124:A-595.
28. Mashimo H, Wu DC, Podolsky DK, et al.: Impaired defense of intestinal mucosa in mice lacking intestinal trefoil facote. Science 1996, 274:262-265.
29. Farrell JJ, Taupin D, Doh T, et al.: TFF2/SP-deficient mice show decreased gastric proliferation, increased acid secretion and increased susceptibility to NSAID injury. J Clin Invest 2002, 109:193-204.
30. Guilford P, Hopkins J, Harraway J, et al.: E-cadherin germline mutations in familial gastric cancer. Nature 1998, 392:402-405.
31. Kim JH, Takahashi T, Chiba I, et.al.: Occurrence of p53 gene abnormalities in gastric carcinoma tumors and cell lines. J Natl Cancer Inst 1991, 51:2926-2931.
32. Victor T, Du Toit R, Jordaan AM et al.: No evidence for point mutations in codons 12, 13 and 61 of the ras gene in a high incidence area for esophageal and gastric cancers. Cancer Res 1990, 50:4911-4914.
33. Stemmermann G, Heffelfinger SC, Noffsinger A, et al.: The molecular biology of esophageal and gastric cancer and their precursors: oncogenes, tumor suppressor genes and growth factors. Hum Pathol 1994, 25:968-981.
34. Farinati FC: Genetic, dietary and environmental factors in the pathogenesis of gastric cancer: study of a high incidence family. Ital J Gastroenterol 1987, 19:321-324.
35. Park WS, Oh RR, Park JY, et al.: Somatic mutations of the trefoil factor family 1 gene in gastric cancer. Gastroenterology 2000, 19:691-698.
36. Li QL, Ito K, Sakakura C, et al.: Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 2002, 09:113-124.
37. Fox JG, Dangler CA, Taylor NS, et al.: High-salt diet induces gastric epithelial hyperplasia and parietal cell loss, and enhances Helicobacter pylori colonization in C57BL/6 mice. Cancer Res 1999, 59:4823-4828.
38. Hansson LE, Nyren O, Hsing AW, et al.: The risk of stomach cancer in patients with gastric or duodenal ulcer disease. N Engl J Med 1996, 335:242-49.
39. Li H, Stoicov C, Houghton J: Hyperosmolarity shifts Fas signaling pathway from apoptosis to proliferation by activation of p38 in gastric mucosal cells [abstract]. Gastroenterology 2003, 124:A-460.
40. Hansson LE, Nyren O, Hsing AW, et al.: The risk of stomach cancer in patients with gastric or duodenal ulcer disease. N Engl J Med 1996, 335:242-249.
41. Dixon M: Acid, ulcers and H. pylori. Lancet 1993, 342:384-385.
42. Dockrey GJ, Varro A, Dimaline R et al.: The gastrins: their biological activities. Annu Rev Physiol 2001, 63:119-139.
43. Calam J: Circulation hormones in peptic ulcer disease. In Gut Peptides: Biochemistry and Physiology. Edited by Walsh JH, Dockray GJ. New York: Raven; 1994:655-673.
44. Azuma T, Magami Y, Habu Y et al.: Carboxyl terminal glycine extended progastrin (gastrin-G) in gastric antral mucosa of patients with gastric or duodenal ulcers and in gastrinoma. J Gastroenterol Hepatol 1990, 5:525-529.
45. Chen D, Zhao CM, Dockray GJ, et al.: Glycine extended gastrin synergizes with gastrin 17 to stimulate acid secretion in gastrin-deficient mice. Gastroenterology 2000, 1199:756-765.
46. Russo F, Jillo E, Clemente C, et al.: Circulating cytokines and gastrin levels in asymptomatic subjects infected by Helicobacter pylori. Immunopharmacol Immunotoxicol 2001, 23:3-24.
47. Wang TC, Dangler CA, Chen D, et al.: Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric cancer. Gastroenterology 2000, 118:36-47.
48. Zivney J, Wang TC, Yantiss R, et al.: Role of therapy or monitoring in preventing progression to gastric cancer. J Clin Gastroenterol 2003, 36:S50-S60.
49. Ohkusa T, Funiki K, Takashimizu I, et al.: Improvement in atrophic gastritis and intestinal metaplasia in patients in whom Helicobacter pylori was eradicated. Ann Intern Med 2001, 34:380-386.
50. Uemura N, Okamoto S, Yamamoto S, et al.: Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001, 345:784-789.
51. Zavros Y, Rieder G, Ferguson A et al.: Genetic or chemical hypochlorhydria is associated with inflammation that modulates parietal and G-cell populations in mice. Gastroenterology 2002, 122:119-133.
52. Parsonnet J, Harris RA, Hack HM et al.: Modeling cost effectiveness of H. pylori screening to prevent gastric cancer: a mandate for clinical trials. Lancet 1996, 348:150-154.
53. Uemura N, Mukai T, Okamoto S, et al.: Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomark Prev 1997, 6:639-642.